Paul Jeng
Stock Analyst at Guggenheim
(3.69)
# 1,990
Out of 4,345 analysts
23
Total ratings
60%
Success rate
17.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMTX Immatics | Maintained: Buy | $19 | $11.19 | +69.79% | 5 | May 12, 2026 | |
| CHRS Coherus Oncology | Initiated Coverage: Buy | $12 | $1.64 | +631.71% | 1 | May 11, 2026 | |
| CNTX Context Therapeutics | Maintained: Buy | $5 | $2.63 | +90.11% | 4 | May 6, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Initiated Coverage: Buy | $45 | $7.91 | +468.90% | 1 | Apr 28, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Buy | $50 → $54 | $29.35 | +83.99% | 6 | Apr 13, 2026 | |
| ADAG Adagene | Maintained: Buy | $10 | $3.72 | +168.82% | 4 | Apr 6, 2026 | |
| IMCR Immunocore Holdings | Initiated Coverage: Hold | n/a | $29.41 | - | 1 | Sep 17, 2025 | |
| TARA Protara Therapeutics | Initiated Coverage: Buy | $50 | $4.80 | n/a | 1 | Jul 29, 2020 |
Immatics
May 12, 2026
Maintained: Buy
Price Target: $19
Current: $11.19
Upside: +69.79%
Coherus Oncology
May 11, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $1.64
Upside: +631.71%
Context Therapeutics
May 6, 2026
Maintained: Buy
Price Target: $5
Current: $2.63
Upside: +90.11%
Corbus Pharmaceuticals Holdings
Apr 28, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $7.91
Upside: +468.90%
IDEAYA Biosciences
Apr 13, 2026
Maintained: Buy
Price Target: $50 → $54
Current: $29.35
Upside: +83.99%
Adagene
Apr 6, 2026
Maintained: Buy
Price Target: $10
Current: $3.72
Upside: +168.82%
Immunocore Holdings
Sep 17, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $29.41
Upside: -
Protara Therapeutics
Jul 29, 2020
Initiated Coverage: Buy
Price Target: $50
Current: $4.80
Upside: n/a